Skip to main content

CSB Bank: Don’t miss this turnaround opportunity

CSB Bank is on its way to transform into a new age bank with a wider presence, offering varied products and using the latest available technology solutions for its operations

Highlights
-Q1 FY21 profit surges
-Gold loans dominate advances book
-Margins expand, operating efficiency improves
-Asset quality improves, credit cost falls
-Aims to transform to a new age bank with backing of a strong promoter
-Valuations reasonable, future looks promising

----------------------------------

CSB Bank a new entrant in the list of listed private-sector lenders is a worthy investment option, even as the banking sector faces pressure due to the economic uncertainty unleashed by COVID-19. Ever since we published a note on the bank’s fourth-quarter FY20 earnings on June 16, its stock price has seen a sharp rally of around 60 percent. Our continuing optimism on the stock meant we recommended it in our weekly tactical pick in July-end.

Our main premise of CSB Bank as a good turnaround story is playing out, as apparent in its earnings in the first quarter of the current fiscal. CSB posted a net profit of Rs 54 crore in Q1 FY21, more than double compared to the figure achieved in the same period last year. Its profit surged despite the bank creating provisions of Rs 43 crore related to COVID-19. Profits were aided by higher margins, better operating efficiency and lower credit costs.

Capital, asset quality and growth are the three big issues confronting banks today. CSB is scoring well on these parameters.

Till FY18, CSB was struggling with very low capital. Its overall capital adequacy ratio at 8.33 per cent in March 2018 was lower than the regulatory requirement of 10.785 per cent. With fresh equity infusion of Rs 1,208 crore by the Fairfax group in FY19 and FY20, there is a sharp increase in CSB’s net worth. The bank’s capitalisation is now strong with capital adequacy ratio at 18.9 percent as of June-end. Moreover, it has assured funding support from the group to meet its future capital requirements.

Talking about asset quality, the new management had initiated a clean-up in the bank’s loan book. Consequently, its asset quality has improved with the gross non-performing assets (GNPA) ratio coming down to 3.5 percent in June from 7.89 percent as of March 31, 2018. Around 18 percent of the bank’s loans are under moratorium. Moreover, the bank’s healthy provisional coverage ratio of 82 percent and additional provisions to meet future contingencies is very encouraging.

While most banks are focusing on balance sheet protection, CSB is one of the few banks that has growth plans for FY21. It plans to open 100 branches in FY21. Pralay Mondal, a veteran banker, who recently joined the bank shall focus on growing CSB’s retail banking business. Mondal spearheaded the retail business of leading private banks like Axis and HDFC Bank in his previous roles.

The bank’s loan book growth was modest at 6 per cent in Q1 FY21 and was obviously impacted by the lockdown. However, gold loans, which constitute 32 per cent of the total book, grew by 28 percent YoY in Q1. The management intends to increase the share of gold loans to 40 percent of the total loan book in the medium term.

CSB’s increased dynamism gets reflected in the fact it is one of few small banks that participated in a big way in RBI’s liquidity measures like TLTRO (Targeted long term repo operations), trying to boost margins.

Overall, with a strong capital base after Fairfax’s investment in CSB, investors can expect a bigger scale of operations and improved profitability for the bank in the medium term.



Key highlights

CSB’s loan book stood at Rs 11,228 crore as at end June. Management guided gold loans to grow by at least 25% in FY21. Also, with Mondal at the helm of affairs, we can expect some traction in new verticals like unsecured loans and MSME loans as well.

The overall deposit base of the bank grew by 8 percent in Q1. Thanks to the management’s conscious strategy of not focusing on bulk deposits, low cost current and saving deposits (CASA) ratio improved to 29 percent in Q1, an increase of 112 bps YoY.



Net interest margin (NIM) improved owing to better cost of funds and improved yield on advances. Average yield on portfolio stood at 10.74 percent in Q1 due to higher yields on gold loans against 10.22 percent a year ago.

Operating efficiency has been a big driver of profits with operating expenses growth contained at 6%. Consequently, the cost-to-income ratio significantly improved to 50 percent. That said, the ratio will trend upwards in coming months as the bank opens new branches.

With the improvement in asset quality metrics, credit costs have reduced and supported its earnings profile. The management has guided for credit costs to remain below 1 percent in FY21.  Thanks to accelerated provisioning, the additional provisions amount to around 1.3% of total loan book.

Capital adequacy ratio dipped compared to the previous quarter (Q4 FY20) as both market and credit risk went up during the quarter due to increased business activity.

Other takeaways

Bank may consider inorganic opportunities to grow in the banking sector.

The management indicated that the parent Fairfax will participate in the government’s plans to privatise 4 public sector banks.

Valuation and view

Overall, with the backing of the Fairfax group, a professional management running the show and adequate capital, CSB is now re-aligning its business model and is on its way to transform into a new age bank with a wider presence, offering varied products and using the latest available technology solutions for its operations.

The bank’s stock price has seen a sharp rally of in last couple of months and surged over 10 percent yesterday on reporting stellar Q1 earnings.  At the current price of Rs 225, the bank is trading at 1.7 times its FY22 estimated book value. The valuation looks reasonable considering improving return ratios and a promising outlook. Despite the rally, we see interest in the stock sustaining as it is one of the few banks reporting earnings growth which can sustain its stock price uptrend in the near term.

In the long term, the stock can be re-rated if the bank succeeds in transforming itself into a new age bank. That said, execution risks remain and a weak macroeconomic environment aggravated by the outbreak of COVID-19 can delay CSB’s progress.

Long term investors looking for growth story in the banking space should buy the stock on dips.

Source - Moneycontrol.com

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...